Skip to content
About Us
Our Focus
Pipeline
Resources
Browse our latest resources
Newsroom
Keep up with our latest news.
Publications
Learn more about our science.
Trail Notes
Insights from our leadership team
Cliffs Notes
Downloadable, infographics and more.
Careers
Investors
Careers
CLINICALTRIALS.GOV
The Crestone Study
Newsroom
Publications
Trail Notes
Cliffs Notes
Newsroom
Keep up with our latest news.
July 2022
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group
Read More
All
Press Releases
Filter by Quarter
3Q 2021
4Q 2021
1Q 2022
2Q 2022
3Q 2022
2Q 2021
1Q 2021
4Q 2020
3Q 2020
August 04, 2022
Press Releases
Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Read More
July 28, 2022
Press Releases
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures
Read More
July 28, 2022
Press Releases
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group
Read More
May 26, 2022
Press Releases
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
Read More
May 25, 2022
Press Releases
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions
Read More
May 05, 2022
Press Releases
Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Read More
Pages:
1
2
3
4
5
Last Page
Load More
Load More
Investor Resources
Follow our journey with our latest
Investor Resources
Press Releases
Read the latest News Releases for Investors
Events
Browse the calendar to view Investor related events and announcements. Webcasts and presentations that have been archived are available by viewing historical event details.
SEC Filings
Review all of Elevation's SEC filings
Track our progress
Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.
Email
*
Email
This field is for validation purposes and should be left unchanged.